SGLT2 inhibitors and how we use them
In this podcast, Dr Rick Cutfield discusses the management of type two diabetes mellitus following the introduction of new funded medication in NZ.
He covers the importance of lifestyle, medication, and support at every step, and also the pharmacological management including the new stepwise approach to management.
Indications and precautions of the new classes of subsidised medications: Sodium glucose co-transporter 2 (SGLT-2) inhibitors, and briefly Glucagon like peptide-1 receptor (GLP-1) agonists are also covered.
Topics:
- 00:37 lifestyle interventions
- 03:18 updated guidelines
- 12:51 UTIs
- 13:48 monitoring
- 14:50 HbA1c maximum drop
- 15:30 reducing hospitalisations
- 20:22 diabetes in NZ going forward
- 21:57 health equity
- 22:20 take-home messages
Take-home messages
|
Resources
- Optimising pharmacological management of HbA1c levels in patients with type 2 diabetes: from metformin to insulin bpacnz (2019)
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure NEJM (2020)
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes NEJM (2016)
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Diabetes Care (2015)
- Proposal to fund two new medicines for type 2 diabetes Pharmac (2020)
- Type 2 Diabetes Management Guidance MOH/NZSSD (2020)
Presenter
Dr Rick Cutfield
Endocrinologist
Dr Rick Cutfield is the Clinical Director of the Endocrinology & Diabetes Division at Waitemata DHB. He is active in teaching, clinical research and all aspects of diabetes, endocrinology and general medicine.
Supported by an independent medical education grant from: